The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaPeter Hillmen, Lucio Luzzatto, Neal S. Young et al.|New England Journal of Medicine|2006Cited by 1.3k
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaRobert A. Brodsky, Peter Hillmen, Neal S. Young et al.|Blood|2007Cited by 653
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantationTetsuichi Yoshizato, Seishi Ogawa, Makoto Onizuka et al.|Blood|2017Cited by 352
Germ line<i>DDX41</i>mutations define a unique subtype of myeloid neoplasmsHideki Makishima, Jaroslaw P. Maciejewski, Ryunosuke Saiki et al.|Blood|2022Cited by 142
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Olivier Nibourel, Caterina Gregorio et al.|Journal of Clinical Oncology|2024Cited by 39